The Use of Faster Acting Aspart in Type 1 Diabetes Patients

Overview

Data on switching from traditional mealtime insulins to fast-acting insulin aspart (Fiasp) in routine clinical practice are sparse. The aim was to evaluate the efficacy and safety of switching from traditional mealtime insulin to Fiasp in a "real-world" clinical practice setting in people with type 1 diabetes in Belgium.

The primary endpoint was the evolution of time in range (TIR, 70-180 mg/dl) at 6 and 12 months. Secondary endpoints included change in HbA1c, BMI, insulin doses, time below range (T\<70 and T\<54 mg/dl) and time above range (T\>180 and T\>250 mg/dl). Retrospective analysis Two-center study

Conditions

Eligibility

Locations (1)

Outcomes